A private equity firm announced the merger of three assets that can reduce payers’s headaches when it comes to making sure that provider-submitted claims are accurate. In turn providers can get paid quickly. The post New Entity Aims to Help Payers Improve Payment Integrity appeared first on MedCity News.
Cancer drugs are always popular biotech investments, but autoimmune disease also figures prominently in the startup financings announced during the annual J.P. Morgan Healthcare Conference this year. The post JPM Deals Recap: Boston Scientific Acquisition, a Mega Round for Parabalis, Enodia Emerges & More appeared first on MedCity News.
Takeda Pharmaceutical’s oveporexton is designed to treat the root cause of narcolepsy. Statistically significant Phase 3 results for the twice daily pill were presented Monday during the World Sleep 2025 Congress in Singapore. The post Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels appeared first on MedCity…
Reinforcing educational standards will enable hygienists to perform more advanced procedures and raise the standard of care. The post Why Strengthening the Dental Hygienist Profession is Key to Solving Our Oral Health Crisis appeared first on MedCity News.
¿Cómo deben usar la inteligencia artificial (IA) las aseguradoras de salud? La respuesta a esta pregunta inusual de política pública, encuentra en un mismo bando al gobernador republicano Ron DeSantis, de Florida, y al gobierno demócrata de Maryland, los dos contra el presidente Donald Trump y el gobernador de California, Gavin Newsom. La regulación de…
Prioritizing risk-based management, data science, smart automation, standards, and patient optionality are critical for the industry to keep up with market changes. The recent FDA guidance that encourages ‘pragmatic trials’ in specific scenarios is a move in the right direction. The post Carving a Path Toward Pragmatic Innovation in Clinical Trials appeared first on MedCity…
Regeneron Pharmaceuticals said the FDA cited no approvability concerns for its multiple myeloma drug, linvoseltamab, other than previously identified issues with a contract manufacturer. While linvoseltamab trails bispecific antibodies currently marketed by Johnson & Johnson and Pfizer, if approved, it could bring patients an earlier treatment option. The post FDA Rejection Delays Regeneron From Competing…
Personalized and highly-targeted therapeutics are becoming more common, making local or regional production increasingly valuable for faster patient access. This underscores how a hybrid network combining large, centralized plants coupled with flexible regional sites will define the next era of resilient biomanufacturing. The post Moving Beyond the Mega-Factory: Why the Future of Biomanufacturing is Agile,…
There is no excerpt because this is a protected post.